載入中
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
收盤時
US$193.95
+US$4.19 · +2.21%
盤後
US$193.5
−US$0.45 · -0.23%
10月12日 下午6:34 ET
盤中時間採用ET。市場資料可能有所延遲。
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
日內區間
目前US$193.95
52週區間
目前US$193.95
盤中時間採用ET。市場資料可能有所延遲。
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
日內區間
目前US$193.95
52週區間
目前US$193.95
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | 1158萬 USD | 3538萬 USD | 2939萬 USD |
| 銷貨成本 | 1655.8萬 USD | — | — | — | — |
| 毛利 | −1655.8萬 USD | — | 1158萬 USD | 3538萬 USD | 2939萬 USD |
| 研究與開發 | 9.79億 USD | 5.92億 USD | 4.23億 USD | 2.53億 USD | 1.87億 USD |
| 銷售、一般及管理費用 | 1.87億 USD | 9729.9萬 USD | 7562.1萬 USD | 4058.6萬 USD | 3045萬 USD |
| 營業費用 | 11.66億 USD | 6.9億 USD | 4.99億 USD | 2.94億 USD | 2.17億 USD |
| 利息收入 | 9069.4萬 USD | 8688.3萬 USD | 4748.2萬 USD | 915.4萬 USD | 92.9萬 USD |
| 利息支出 | 2423.1萬 USD | — | 30.3萬 USD | — | 1.2萬 USD |
| 折舊和攤銷 | 1655.8萬 USD | 1182.4萬 USD | 930.9萬 USD | 965.6萬 USD | 733.2萬 USD |
| 營業利益 | −11.82億 USD | −6.9億 USD | −4.87億 USD | −2.58億 USD | −1.88億 USD |
| 淨利 | −11.31億 USD | −6億 USD | −4.36億 USD | −2.49億 USD | −1.87億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI13.2億0.06%2.3兆 USD0.03%US$381.57-0.10%
Vanguard Morningstar Small-Cap ETFVB9.55億0.51%1853億 USD0.03%US$288.16-0.46%
Vanguard Morningstar Small-Cap Growth ETFVBK5.48億1.20%447億 USD0.05%US$340.88-1.12%
Vanguard Extended Market ETFVXF4.77億0.49%954億 USD0.05%US$233.52-0.63%
iShares Biotechnology ETFIBB2.84億2.62%108.2億 USD0.44%US$204.26-1.08%
iShares Russell Mid-Cap Growth ETFIWP2.04億1.02%200.95億 USD0.23%US$140.99-1.47%
iShares Russell Mid-Cap ETFIWR1.51億0.27%567.65億 USD0.18%US$109.47-0.32%
iShares Russell 1000 Growth ETFIWF1.36億0.10%1305.08億 USD0.18%US$127.13-0.61%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPiShares Russell Mid-Cap ETFIWRiShares Russell 1000 Growth ETFIWFAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
